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We would like to thank Dr Cummings for giving us the opportunity to explain our study results. Results from nine randomized, controlled, trials (RCTs), [1] [2] [3] [4] [5] [6] [7] [8] [9] including the one that has been just published (e-pub ahead of print) by Dizdar et al. 9 and meta-analyses [10] [11] [12] comparing animal-derived surfactants, namely, poractant alfa (PA), beractant (BE), bovactant (BO) and/or calfactant (CA), have consistently shown faster weaning of oxygen and mean airway pressure, less need for redosing, fewer days on oxygen and mechanical ventilation, shorter length of stay (LOS) as well as survival advantage in babies treated with PA. These advantages with PA over BE, CA or BO are likely related to major biological and/or biochemical differences between these animal-derived surfactant preparations. PA contains the highest amount of phospholipids when compared with BE or CA. Higher amount of phospholipids has been shown to downregulate oxidative functions in monocytes and confer better anti-inflammatory properties. 13 In addition, bacterial growth in different surfactant preparations is influenced by microbial species and the composition and dose of the surfactant. PA was bactericidal in a dose-dependent fashion and differed from BE and BO, a surfactant preparation similar to CA.
14 PA contains the highest amount of plasmalogens (PL) when compared with BE. 15 BO contains the lowest amount of PL. 15 PL are anti-oxidant phospholipids and presence of higher amounts of PL in the tracheal aspirates from pre-term infants has been shown to be associated with a lower risk for bronchopulmonary dysplasia (BPD). 16 Also, the amount of surfactant-associated protein B (SP-B) is highest in PA when compared with BE or CA. SP-B is the most important SP in helping the phospholipids to rapidly adsorb at the air-liquid interphase and in decreasing surface tension. Furthermore, the phospholipid molecular species of PA is much closer to that of human surfactant. 17, 18 In our paper, 19 we have clearly acknowledged the limitations of the retrospective study and took steps to minimize any shortcomings. The major finding of lower mortality in PA-treated infants is consistent with results from previously published small RCTs as well as meta-analyses comparing PA and BE. None of the studies comparing BE with CA have shown any differences in the need for redosing, days on oxygen or mechanical ventilation, BPD or mortality. Interestingly, Bloom et al. 1 reported a higher mortality rate in infants with a birth weight <600 g treated with CA as compared with BE (63% vs 26%, P<0.007). However, this finding was not duplicated in a retrospective study using a database, similar to our study, published by Clark et al.
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In regards to the concern regarding results of the PA versus BE RCT published in 2004, Ramanathan et al. 6 had clearly stated, a priori, under the methods section that they would evaluate 'oxygen requirement at 36 weeks post-conceptional age for infants born at p32 weeks gestation, and mortality' as secondary outcomes. Therefore, this was not a post hoc analysis as stated in the review article by Holm and Cummings. 21 Responses to specific comments (1) A different study, published as an abstract in 2007, and using the Premier database, applied a different time frame, patient population and statistical approach, and reached similar conclusions, namely survival advantage with PA when compared with BE or CA. 22 In the 2007 abstract, the authors noted that 10 237 of the 24 907 patients meeting basic study criteria were included in the adjusted analysis resulting from the regression model; this was deemed acceptable, as unknown (unreported, missing or invalid) values of the covariates do not permit appropriate adjustment for case mix. In the current study, there were 8276 patients who met the selection criteria, yet were excluded due to unreported, missing or invalid entries for one or more of the variables: gender, race, APR-DRG, gestational age or birth weight. The exclusion of these left 14 173 patients for use in the revised regression models, which now also accounted for center effects. Furthermore, the outcome that was analyzed in this paper was limited to mortality only. ( 2) The lower mortality observed with PA treatment cannot be attributed to the idea that a less ill or more mature population received this treatment. In the analysis stratified by birth weight, the lowest mortality rate was always observed in the PA group, except for the category 1250-1499 g. In fact, our study results of decreased mortality coupled with fewer days on oxygen and mechanical ventilation has been reported in a recent meta-analysis comparing porcine versus bovine-derived surfactants. 12 We did not cite the report by Trembath et al. 23 in which they described trends in surfactant use due to the clearly different objective (no pre-specified analysis on mortality) and population (more mature infants with no specified RDS diagnosis) compared with our study. In the population considered by Trembath et al., 23 it may be difficult to demonstrate significant differences between treatments in terms of mortality due to the limited number of deaths observed. ( 3) The analysis reported in this paper 19 did not have the aim of evaluating differences between surfactants in terms of LOS. In the recent meta-analysis 12 comparing porcine versus bovine-derived surfactants, the length of hospital stay was significantly shorter for infants treated with PA, compared with those treated with BE (weighted mean difference: 26.3 fewer days (95% CI: 36.6 to 16.1); P<0.00001). Additionally, it is not generally considered appropriate to adjust the results of one outcome measure (for example, mortality) for another outcome measure (LOS). Adjustments for case mix and mortality risk by APR-DRGs are very commonly done in studies involving large databases, such as the one that was used in our study. The appropriateness of APR-DRG's method in terms of structure and statistical performance in neonatal medicine has been extensively discussed by Muldoon. 24 Moreover, only 69 patients in our study lacked APR-DRG information, so severity of illness was accounted for in our study. In addition, the data on maturity (gestational age and birth weight) presented in our paper and accounted for in our mortality regression modeling, help rule out differences in maturity as a substantial explanation for the differences in mortality results.
As stated previously, there have been no significant differences in the three RCTs comparing CA with BE. [1] [2] [3] In the review article by Holm and Cummings, 21 they did not state the mortality differences between PA and BE from RCTs.
Surfactant dosing has clearly been shown to affect the clinical outcomes. Following is the discussion by Singh et al. 12 from the most recent meta-analysis:
Despite these limitations, this meta-analysis differs from other reviews in that it includes the largest number of RCTs comparing poractant alfa and beractant, with a fairly large cumulative sample size. The superior outcomes noted in this meta-analysis with poractant alfa, compared with beractant, particularly with respect to reductions in mortality rates, the need for redosing and initial respiratory support, might be attributable to differences in the biochemical and biophysical properties of poractant alfa itself or to the initial higher dose (200 mg kg À1 ) used. The higher dose of poractant alfa, with greater contents of phospholipids and surfactant-associated proteins B and C, might have resulted in greater improvements in lung function and hence better outcomes. Because the low dose of poractant alfa (100 mg kg À1 ) did not have the same effects on mortality and redosing rates as did the high dose of poractant alfa, it seems that the greater concentrations of phospholipids and surfactant proteins in a given volume might be responsible for the observed superior effects when high-dose poractant alfa is compared with beractant at the dosage volumes recommended by the manufacturers.
In the five RCTs comparing PA 200 mg kg À1 with BE 100 mg kg À1 , faster weaning of oxygen and peak inspiratory pressure, less need for redosing, fewer cases of air leaks and clinically significant patent ductus arteriosus and earlier extubations in PA-treated infants have been reported. 4, [6] [7] [8] [9] These acute benefits in PA-treated infants could potentially result in shorter LOS. In fact, in the most recent RCT, Dizdar et al. 9 reported significantly more infants surviving without BPD (78.7 vs 58.5%, P ¼ 0.015) without increase in LOS in the PA-treated group versus BE group. There was also a trend towards fewer deaths in PA-vs BE-treated patients (9.8 vs 20%). In a meta-analysis by Fox and Sothinathan, 10 PA-treated infants were less likely to need more than one dose than those treated with BE (37 vs 53%; RR 1.36; 95% CI 1.08, 1.72). In a multicenter RCT, comparing high versus lowdose bovine surfactant, Surfactant-TA, Konishi et al. 25 showed significantly less intraventricular hemorrhage and BPD in pre-term infants treated with the high dose. In a study comparing highversus low-dose BO, Gortner et al. 26 reported that high-dose BO improved oxygenation and reduced barotrauma. In a study of single versus multiple doses of PA by Speer et al. 27 multiple dose treatment resulted in a reduced incidence of pneumothorax (18 vs 9%, P<0.001) and more importantly, a reduction in mortality (21 vs 13%, P<0.05). Our results do not conflict with data from an earlier randomized prospective trial that included more than 10-fold greater number of PA-treated infants. 28 We did not discuss this study because the 'low-dose' PA-treated group could receive a maximum cumulative total of 300 mg kg À1 or in the 'high-dose' group, up to a maximum cumulative total dose of 600 mg kg À1 . The mean total amount of PA given in the 'low-dose' group was 242 mg phospholipid per kg, probably enough to replace the entire pulmonary surfactant pool, according to the study authors. In this study, they did find a significant difference with 48.4% of babies in the 'low-dose' group needing >40% oxygen after 3 days compared with 42.6% of those in the 'high-dose' group (P<0.01). Cogo et al. 29 recently reported on the pharmacokinetics in pre-term infants treated with 100 or 200 mg kg À1 of PA. The disaturated, phosphatidyl choline (DSPC) half-life was significantly longer and fewer babies required additional doses, as well as improvement in oxygenation index with the higher dose of PA. Based on evidence, European Consensus Guidelines (2010 update) 30 recommended an initial dose of 200 mg kg À1 of PA for early rescue treatment of RDS. Use of higher dose of PA has also been endorsed by the European Association of Perinatal Medicine.
We sincerely thank Dr Cummings for his comments and the Journal Editor for giving us the opportunity to clarify all the issues that were brought to our attention.
